爱美客前三季度实现营业收入18.65亿元 研发费用同比增26.67%

Core Insights - Aimeike achieved a revenue of 1.865 billion yuan and a net profit of 1.093 billion yuan in the first three quarters of 2025 [1] - The company has a strong liquidity position with cash and cash equivalents of 1.18 billion yuan and trading financial assets of 1.973 billion yuan as of September 30, 2025 [1] - Aimeike's cash flow from operating activities for the first three quarters was 1.073 billion yuan, indicating robust cash generation capabilities [1] Financial Performance - Aimeike distributed cash dividends, profits, or interest payments totaling 1.513 billion yuan in the first three quarters [1] - Research and development expenses increased by 26.67% year-on-year to 237 million yuan, reflecting the company's commitment to innovation [1] - Other income reached 52.185 million yuan, and fair value changes contributed 64.307 million yuan to the financial results [2] Strategic Developments - The acquisition of a controlling stake in South Korea's REGENBiotech, Inc. resulted in a 233.54% increase in intangible assets compared to the previous year [2] - Fixed assets grew by 47.75% year-on-year, and non-current assets due within one year increased by 60.57%, primarily due to an increase in short-term financial products [2] - Aimeike's strategic initiatives include entering the hair regeneration market with the approval of Minoxidil topical solution and the registration of a new cosmetic ingredient, Glycyrrhetinic Acid A [1]